RxDoctor Payments Data

Thomas Martin, MD

Pulmonary Disease · Athens, GANPI 1245410653

Payments from drug & device makers

$4,940in general payments, 2019–2025

Across 38 payments — averaging $129.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • GSK$169
  • AstraZeneca$160
  • Insmed, Inc.$50
  • Sunovion Pharmaceuticals Inc.$36
  • Pfizer$31
  • plus $118 from 6 others

What the payments were for

  • Travel & lodging$3607%
  • Food & beverage$53911%
  • Education$4,04182%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,940 in reported general payments places this provider in the 45th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$145,427
Medicare patients
469
Services billed
1,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter391$284,131
Breo ElliptaFluticasone/Vilanterol167$76,979
Stiolto RespimatTiotropium Br/Olodaterol Hcl81$53,247
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr82$43,056
Breztri AerosphereBudesonide/Glycopyr/Formoterol61$38,943
Spiriva RespimatTiotropium Bromide37$23,311
SymbicortBudesonide/Formoterol Fumarate47$11,378
Spiriva HandihalerTiotropium Bromide21$10,530
Fluticasone-SalmeterolFluticasone Propion/Salmeterol68$10,217
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate72$9,867
Albuterol Sulfate HfaAlbuterol Sulfate270$8,089
Advair HfaFluticasone Propion/Salmeterol15$6,524
Bevespi AerosphereGlycopyrrolate/Formoterol Fum11$5,901
Atrovent HfaIpratropium Bromide12$5,572
Wixela InhubFluticasone Propion/Salmeterol35$4,790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$169$404,166640 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$160$56,221119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →